Multiple collagenase injections are safe for treatment of Dupuytren's contractures.

The authors report the case of a 65-year-old, right-hand-dominant man who had severe Dupuytren's disease with multiple cords and flexion contractures of the metacarpophalangeal and proximal interphalangeal joints of both hands and underwent repeated collagenase injections for treatment. Collagenase has been shown to be safe and effective in the treatment of Dupuytren's contractures when administered as a single dose, but the results of multiple injections over a prolonged period are unknown. Antibodies to collagenase develop in all patients after several treatments, raising concerns about safety and efficacy as a result of sensitization from repeated exposures. The antibodies generated as a result of repeated exposure to collagenase could theoretically render it less effective with time and could also lead to immune reactions as severe as anaphylaxis. The authors present the case of a single patient who experienced continued correction of his contractures with only minor and self-limited adverse reactions after administration of 12 collagenase doses through 15 injections during a 4-year period. Over time, the injections continued to be effective at correcting metacarpophalangeal joint contractures, but less effective at correcting proximal interphalangeal joint contractures. The patient did eventually require a fasciectomy, but the safety and modest success of the repeated collagenase injections shows promise for a less invasive treatment with a better risk profile than open fasciectomy. Although further studies are needed, repeated administration of collagenase appears to be safe and modestly effective for severe Dupuytren's contractures, although a fasciectomy may ultimately be required in the most severe cases.

[1]  Roland Koller-Eichhorn,et al.  Assessment of Potential Cross-Reactivity of Human Endogenous Matrix Metalloproteinases with Collagenase Clostridium histolyticum Antibodies in Human Sera Obtained from Patients with Dupuytren's Contracture , 2012, Clinical and Vaccine Immunology.

[2]  M. Worrell Dupuytren's disease. , 2012, Orthopedics.

[3]  P. Blazar,et al.  Dupuytren Disease: An Evolving Understanding of an Age‐old Disease , 2011, The Journal of the American Academy of Orthopaedic Surgeons.

[4]  G. Holzer,et al.  Kollagenase Clostridium histolyticum im Management der Dupuytrenschen Kontraktur , 2011, Handchirurgie Mikrochirurgie Plastische Chirurgie.

[5]  F. Kaplan Collagenase clostridium histolyticum injection for the treatment of Dupuytren's contracture. , 2011, Drugs of today.

[6]  V. Hentz,et al.  The treatment of Dupuytren disease. , 2011, The Journal of hand surgery.

[7]  S. K. Lee Collagenase Injection as Nonsurgical Treatment of Dupuytren's Disease: 8-Year Follow-Up , 2011 .

[8]  D. Zelouf Injectable Collagenase Clostridium Histolyticum: A New Nonsurgical Treatment for Dupuytren's Disease , 2011 .

[9]  W. Hammert,et al.  Dupuytren contracture. , 2011, The Journal of hand surgery.

[10]  V. Hentz,et al.  Collagenase clostridium histolyticum for Dupuytren's contracture , 2010, Expert opinion on biological therapy.

[11]  Apurva S. Shah,et al.  New treatment options for Dupuytren's surgery: collagenase and percutaneous aponeurotomy. , 2010, The Journal of hand surgery.

[12]  V. Hentz,et al.  Injectable collagenase clostridium histolyticum for Dupuytren's contracture. , 2009, The New England journal of medicine.

[13]  G. Rayan Nonoperative treatment of Dupuytren's disease. , 2008, The Journal of hand surgery.

[14]  G. Molenaers,et al.  Safety and efficacy of botulinum toxin type A following long‐term use , 2006, European journal of neurology.

[15]  M. Meek,et al.  Results of Partial Fasciectomy for Dupuytren Disease in 261 Consecutive Patients , 2006, Annals of plastic surgery.

[16]  B. Goldberger,et al.  Fatal case of BOTOX-related anaphylaxis? , 2005, Journal of forensic sciences.

[17]  J. Jankovic,et al.  Safety of botulinum toxin type A: a systematic review and meta-analysis , 2004, Current medical research and opinion.

[18]  V. Hentz,et al.  Collagen as a clinical target: nonoperative treatment of Dupuytren's disease. , 2002, The Journal of hand surgery.

[19]  A. Klein Complications and adverse reactions with the use of botulinum toxin. , 2001, Seminars in cutaneous medicine and surgery.

[20]  K. Wohlfarth,et al.  Botulinum A Toxin Therapy: Neutralizing and Nonneutralizing Antibodies—Therapeutic Consequences , 1997, Experimental Neurology.

[21]  M. Tylicki [Dupuytren's disease]. , 1966, Wiadomosci lekarskie.